Clene Inc. – NASDAQ:CLNNW

Clene stock price today

$0.035
-0.00
-0.85%
Financial Health
0
1
2
3
4
5
6
7
8
9

Clene stock price monthly change

-12.50%
month

Clene stock price quarterly change

-12.50%
quarter

Clene stock price yearly change

-7.89%
year

Clene key metrics

Market Cap
34.31M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-0.47
Revenue
620K
EBITDA
-52.05M
Income
-48.81M
Revenue Q/Q
-31.77%
Revenue Y/Y
12.72%
Profit margin
-6325.16%
Oper. margin
-10234.46%
Gross margin
94.5%
EBIT margin
-10234.46%
EBITDA margin
-8396.45%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Clene stock price history

Clene stock forecast

Clene financial statements

Clene Inc. (NASDAQ:CLNNW): Profit margin
Jun 2023 269K -25.14M -9346.84%
Sep 2023 108K -2.41M -2238.89%
Dec 2023 170K -10.17M -5984.12%
Mar 2024 73K -11.08M -15178.08%
Clene Inc. (NASDAQ:CLNNW): Debt to assets
Jun 2023 67845000 46.31M 68.26%
Sep 2023 60433000 39.02M 64.58%
Dec 2023 52341000 38.95M 74.42%
Mar 2024 45069000 40.80M 90.54%
Clene Inc. (NASDAQ:CLNNW): Cash Flow
Jun 2023 -7.02M 39K 37.83M
Sep 2023 -6.76M -48K -237K
Dec 2023 -7.21M -6.21M 35.51K
Mar 2024 -7.08M 70.99K -19K

Clene alternative data

Clene Inc. (NASDAQ:CLNNW): Employee count
Jan 2024 75
Feb 2024 75
Mar 2024 82
Apr 2024 82
May 2024 82
Jun 2024 82
Jul 2024 82

Clene other data

0.01% -1.45%
of CLNNW is owned by hedge funds
8.32K -921.98K
shares is hold by hedge funds
  • What's the price of Clene stock today?

    One share of Clene stock can currently be purchased for approximately $0.04.

  • When is Clene's next earnings date?

    Unfortunately, Clene's (CLNNW) next earnings date is currently unknown.

  • Does Clene pay dividends?

    No, Clene does not pay dividends.

  • How much money does Clene make?

    Clene has a market capitalization of 34.31M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 38.27% to 654K US dollars.

  • What is Clene's stock symbol?

    Clene Inc. is traded on the NASDAQ under the ticker symbol "CLNNW".

  • What is Clene's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Clene?

    Shares of Clene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Clene have?

    As Jul 2024, Clene employs 82 workers.

  • What is Clene's official website?

    The official website for Clene is clene.com.

  • How can i contact Clene?

    Clene can be reached via phone at 801 676 9695.

Clene company profile:

Clene Inc.

clene.com
Exchange:

NASDAQ

Full time employees:

82

Industry:

Biotechnology

Sector:

Healthcare

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

6550 South Millrock Drive
Salt Lake City, 84121

CIK: 0001822791
ISIN: US1856341102
CUSIP: 185634110